Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers

Trial Profile

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs AMY 101 (Primary) ; AMY 101 (Primary)
  • Indications Membranous glomerulonephritis; Paroxysmal nocturnal haemoglobinuria; Periodontitis; Renal failure
  • Focus Adverse reactions; First in man
  • Sponsors Amyndas Pharmaceuticals
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 25 Oct 2017 Planned End Date changed from 31 Oct 2017 to 30 Nov 2017.
    • 25 Oct 2017 Planned primary completion date changed from 31 Oct 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top